Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Menasché, P.
Right arrow Articles by Hagège, A. A.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Menasché, P.
Right arrow Articles by Hagège, A. A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The European Society of Cardiology 2006. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Myoblast transplantation during cardiac surgery

Philippe Menasché1,*, Michel Desnos2 and Albert A. Hagège2

1 Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Department of Cardiovascular Surgery; University Paris-5, Faculty of Medicine; INSERM U 633, 20 rue Leblanc, 75015 Paris, France
2 Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Department of Cardiology; Faculty of Medicine, University Paris-Descartes, INSERM U 633, Paris, France

* Corresponding author.E-mail address: philippe.menasche@egp.aphp.fr

After a decade of experimental work, skeletal myoblast transplantation has now entered the clinical arena as a potentially new means of improving the function of the chronically infarcted heart through regeneration of fibrotic scars. Because the engrafted myoblasts do not connect with the host cardiomyocytes, it is increasingly considered that the functional benefits of myogenic cell transplantation are more related to limitation of adverse post-infarction remodelling and/or paracrine signalling on recipient tissue rather than to a synchronous contribution of the graft to the heart's systolic function. The initial clinical studies of intra-operative myoblast transplantation have primarily documented the feasibility of the procedure and unravelled a potential pro-arrhythmic risk that needs to be further characterized. It is now critical to assess whether the functional benefits observed in the laboratory setting translate into meaningful improvements in local and global contractility and ultimate patient outcomes. The results of ongoing randomized trials should soon help clarifying this efficacy issue. In parallel, experimental studies need to be actively pursued to address some remaining key issues including the means of optimizing myoblast delivery, engraftment and survival, and the development of a second-line generation of cells featuring the potential of a true electromechanical integration within the recipient myocardium.

Key Words: Skeletal myoblasts • Transplantation • Stem cells • Myocardial infarction • Heart failure


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.